Canakinumab Study in Individuals With Newly Diagnosed Type 1 Diabetes

Inclusion Criteria: * Between the ages of 6-45 years * Be within 3-months (100 days) of diagnosis of type 1 diabetes * Must have at least one diabetes-related autoantibody present * Must have stimulated C-peptide levels \>0.2 pmol/ml measured during a mixed meal tolerance test (MMTT) conducted at least 21 days from diagnosis and within 37 days of randomization * If participant is female with reproductive potential, she must be willing to avoid pregnancy and have a negative pregnancy test during the 12 months of treatment and for an additional 3 months after completing treatment * Be at least one month from time of last live immunization received * Willing to forgo live vaccinations for 24 months * Must be willing to comply with intensive diabetes management * Must weigh at least 20 kg (44 lbs) at study entry Exclusion Criteria: * Are immunodeficient or have clinically significant chronic lymphopenia (low white blood cell count) * Have an active infection * Have a positive PPD test result * Be currently pregnant or lactating, or anticipate getting pregnant * Ongoing use of medications known to influence glucose tolerance * Require use of other immunosuppressive agents * Have serologic evidence of current or past HIV, Hepatitis B, or Hepatitis C infection * Have any complicating medical issues or abnormal clinical laboratory blood counts or results that interfere with study conduct; history of malignancies * Be currently participating in another type 1 diabetes treatment study